Abstracts tagged "rheumatoid arthritis (RA) and serologic tests"

Abstract Number: 1504 • 2018 ACR/ARHP Annual Meeting
Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study
Alistair Reid^1,2,3, Michael D Wiese⁴, Robert Metcalf⁵, Mihir D Wechalekar^6,7, Anita Lee^8,9, Catherine Hill^2,10,11, Cindy Hall⁸, Leah McWilliams⁵, Les Cleland⁸ and Susanna Proudman¹², ¹Rheumatology, Royal Adelaide Hospital, NORTH ADELAIDE, Australia, ²Medicine, The University of Adelaide, Adelaide, Australia, ³Medicine, University of Wollongong, Wollongong, Australia, ⁴School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ⁵Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia, ⁷Rheumatology, Flinders University, Adelaide, Australia, ⁸Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁹Rheumatology, University of Adelaide, Adelaide, Australia, ¹⁰The Queen Elizabeth Hospital, Adelaide, Australia, ¹¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ¹²Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia
Background/Purpose: Anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) define “seropositive” rheumatoid arthritis (RA). Both predict disease course, development of extra-articular features and treatment outcomes.…
Abstract Number: 1389 • 2017 ACR/ARHP Annual Meeting
Serum Progranulin Antibodies (PGRN-abs) in Rheumatoid Arthritis Patients Being Negative for RF-IgM and ACCP-IgG
Gunter Assmann¹, Silke Zinke², Moritz Gerling³, Natalie Fadle³, Klaus Dieter Preuss³, Michael Pfreundschuh³ and Lorenz Thurner³, ¹Medicine I, University Medical School of Saarland, 66424, Germany, ²Rheumapraxis, Rheumatology Center Berlin - Lichtenberg, Berlin, Germany, ³Medicine I, Jose Carreras Center, University of Saarland, Homburg, Germany
Background/Purpose: Until recently, most research on progranulin (PGRN) had been focused on its role in neurogenerative diseases as frontotemporal dementia. After the detection of elevated…
Abstract Number: 494 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice
Dmitry Karayev¹, Guoqiu Shen¹, Yvonne Lam¹, Andrew Rimmer¹, Nayan Lal¹, Eugene Karayev¹, Kristine Azarraga¹, Ronald A. Blum¹, Allan L. Metzger¹, Robert I. Morris¹ and Arash A. Horizon², ¹Rheumatology Diagnostics Laboratory, Inc. (RDL), Los Angeles, CA, ²Center for Rheumatology Medical Group, Los Angeles, CA
Background/Purpose: RA is the most common autoimmune inflammatory joint disease, affecting up to 1% of the world population. Detection of antibodies, specifically against IgM rheumatoid…
Abstract Number: 933 • 2016 ACR/ARHP Annual Meeting
Erosion Patterns in Seropositive and Seronegative Rheumatoid Arthritis: A Joint-By-Joint Approach
Ottar Gadeholt¹, Katharina Hausotter², Hannes Eberle³, Hans-Peter Tony⁴, Marc Schmalzing⁵ and Thorsten Klink², ¹Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ²Radiology, University Clinic Wuerzburg, Wuerzburg, Germany, ³Medicine, Kreiskliniken Esslingen, Nürtingen, Germany, ⁴Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ⁵Rheumatology/Clinical Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany
Background/Purpose: Rheumatoid arthritis (RA) can be differentiated according to rheumatoid factor (RF) and citrullinated peptide antibodies (ACPA). It is unclear whether seropositive RA (spRA) and…
Abstract Number: 2697 • 2015 ACR/ARHP Annual Meeting
Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia
Jayanth Doss¹, Huan Mo², Leslie J. Crofford¹ and Joshua C. Denny², ¹Rheumatology, Vanderbilt University School of Medicine, Nashville, TN, ²Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN
Background/Purpose: The differences between seronegative and seropositive rheumatoid arthritis (RA) have not been widely reported. We performed an electronic health record (EHR)-based phenome-wide association study…
Abstract Number: 2161 • 2014 ACR/ARHP Annual Meeting
Interest of Systematic Lyme Serology in Context of Recent Onset Arthritis
Dewi Guellec¹, Valérie Narbonne², Divi Cornec³, Thierry Marhadour⁴, Maxime Dougados⁵, Jean-Pierre Daures⁶, Sandrine Jousse-Joulin¹, Valerie Devauchelle⁷ and Alain Saraux⁸, ¹Rheumatology, CHU Brest, Brest, France, ²Microbiology, CHU Brest, Brest, France, ³Department of rheumatology and unit of immunology, Brest Occidentale University, Brest, France, ⁴Rheumatology, CHU de la Cavale Blanche, Brest, France, ⁵INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁶Biostatistic, INSERM, Montpellier, France, ⁷Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ⁸Rhumatologie, CHU Brest and EA 2216, UBO, Brest, France
Background/Purpose Lyme arthritis is a late manifestation of a tick-transmitted spirotechal infection, mainly caused by Borrelia burdorgferi. Lyme arthritis typically presents as a mono- or…
Abstract Number: 1054 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis
Daniel Aletaha¹, Farideh Alasti² and Josef Smolen³, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose To investigate the associations of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPA) with rheumatoid arthritis (RA) disease activity.Methods We analyzed the association…
Abstract Number: 1788 • 2013 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Test (Vectra^® DA) Estimates Risk Of Radiographic Progression For Patients With Rheumatoid Arthritis From The Leiden Early Arthritis Clinic
Wanying Li¹, DJ Haney¹, Guy Cavet¹, Thomas W. Huizinga², Eric H. Sasso¹ and A. H. M. van der Helm-van Mil³, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The multi-biomarker disease activity (MBDA) blood test assesses disease activity in patients with rheumatoid arthritis (RA) using a validated algorithm to provide a score…
Abstract Number: 1704 • 2013 ACR/ARHP Annual Meeting
Mapping The Shared and Distinct HLA Alleles For Seropositive and Seronegative Rheumatoid Arthritis
Buhm Han¹, Stephen Eyre², Dorothee Diogo¹, John Bowes³, Yukinori Okada¹, Leonid Padyukov⁴, Robert M. Plenge⁵, Lars Klareskog⁶, Jane Worthington⁷, Peter K. Gregersen⁸, Paul de Bakker⁹ and Soumya Raychaudhuri¹, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁴Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁶Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁷Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁸Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁹Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Investigators have long speculated that the two subtypes of rheumatoid arthritis (RA), anti-citrullinated protein autoantibody positive (ACPA+) and negative (ACPA-), have distinct underlying genetic…
Abstract Number: 2118 • 2012 ACR/ARHP Annual Meeting
Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, George A. Wells⁴, Joan M. Bathon⁵, Clifton O. Bingham III⁶, Vivian P. Bykerk⁷, Mikkel Ostergaard⁸, Hilde B. Hammer⁹, Maarten Boers¹⁰, Paul Peter Tak¹¹, Oliver M. FitzGerald¹², Christopher T. Ritchlin¹³, Dafna D. Gladman¹⁴, Philip J. Mease¹⁵, Dirkjan van Schaardenburg¹⁶, Marina Backhaus¹⁷, Bernard Combe¹⁸, Gianfranco Ferraccioli¹⁹ and Anthony Marotta²⁰, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Epidemiology & Community Med, Univ of Ottawa Faculty of Med, Ottawa, ON, Canada, ⁵Columbia University, New York, NY, ⁶Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Dept of Rheumatology RM, Copenhagen University Hospital, Glostrup, Denmark, ⁹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁰Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ¹¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹²Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ¹³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Swedish Rheumatology Research Group, Seattle, WA, ¹⁶Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ¹⁷Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹⁸Rheumatology, Hopital Lapeyronie, Montpellier, France, ¹⁹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²⁰Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The OMERACT soluble biomarker sub-committee has published validation criteria related to truth, discrimination and feasibility for biomarkers reflecting structural damage1. The large majority of…
Abstract Number: 977 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Novel Citrullination Target in Rheumatoid Arthritis That Enhances Diagnostic Utility in Anti-CCP Negative Patients
Walter P. Maksymowych¹, Vivian P. Bykerk², Désirée van der Heijde³, R. Landewe⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: 14-3-3 eta is normally an intracellular protein and only in the disease state is it released into the extracellular space. We have previously presented…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].